ExamFinch.com My Study

Study guide

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction

Practice this exam

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction

Key Takeaways Explain This Topic AI

ST-elevation myocardial infarction (STEMI) mandates emergent reperfusion with primary percutaneous coronary intervention (PCI) within 90 minutes of first medical contact, supported by dual antiplatelet therapy (aspirin plus ticagrelor or prasugrel; intravenous cangrelor if oral administration is delayed or impossible) and unfractionated heparin.

Type 1 myocardial infarction arises from acute atherothrombotic plaque rupture or erosion requiring immediate revascularization and antithrombotic therapy, whereas Type 2 myocardial infarction reflects supply-demand mismatch in critically ill patients (e.g., severe sepsis, hypoxemia, tachyarrhythmias, shock) requiring correction of the underlying physiological trigger rather than empiric PCI or antithrombotics.

Post-infarction mechanical complications peak 3 to 7 days post-MI: Ventricular Septal Rupture (VSR) presents with a harsh holosystolic murmur, palpable thrill, and oxygen saturation step-up >= 7% from RA to RV/PA; Papillary Muscle Rupture involves the posteromedial papillary muscle (solitary supply from the PDA) causing acute flash pulmonary edema, giant v-waves on PCWP tracings, and a frequently soft or absent murmur; Free Wall Rupture presents either as acute catastrophic blowout with cardiac tamponade and PEA arrest or as a surgically salvageable pseudoaneurysm.

Right ventricular (RV) infarction accompanies 30% to 50% of inferior STEMIs (proximal RCA occlusion) and manifests as the classic triad of hypotension, clear lung fields, and elevated jugular venous pressure (Kussmaul sign), confirmed by >= 1 mm ST elevation in lead V4R; hemodynamic stability requires aggressive isotonic crystalloid volume loading and strict avoidance of preload-reducing agents (nitrates, morphine, and diuretics).

Last updated: October 2026

Acute Coronary Syndromes in the Intensive Care Unit

Acute coronary syndromes (ACS) encountered in the intensive care unit present unique diagnostic and therapeutic challenges. Critically ill patients may develop acute myocardial infarction (AMI) either as the primary reason for admission or as a secondary complication of severe systemic physiological derangements. Rapid risk stratification, differentiation between ST-elevation myocardial infarction (STEMI) and non-ST-elevation acute coronary syndromes (NSTE-ACS), and prompt therapeutic execution are critical determinants of survival.

Primary PCI Timing and Reperfusion Strategies

For patients presenting with STEMI or new left bundle branch block (LBBB) with clinical suspicion of acute transmural ischemia, immediate mechanical reperfusion is paramount:

Primary Percutaneous Coronary Intervention (PCI) : The standard of care when door-to-balloon time can be achieved within ≤ 90 minutes \le 90\text{ minutes} ≤ 90 minutes at a PCI-capable center, or within ≤ 120 minutes \le 120\text{ minutes} ≤ 120 minutes of first medical contact when transfer from a non-PCI center is required.

Fibrinolytic Therapy : Indicated when transfer to a PCI-capable facility within 120 minutes 120\text{ minutes} 120 minutes is impossible and no absolute contraindications exist (e.g., prior intracranial hemorrhage, active internal bleeding, ischemic stroke within 3 months). Systemic fibrinolytics (tenecteplase, alteplase, or reteplase) should be administered within ≤ 30 minutes \le 30\text{ minutes} ≤ 30 minutes of arrival ("door-to-needle" time), followed by routine transfer to a PCI center for emergent angiography.

In Non-ST-Elevation ACS (NSTEMI / Unstable Angina) , management hinges on clinical risk stratification:

Immediate Invasive Strategy ( < 2 hours < 2\text{ hours} < 2 hours ) : Mandated for patients exhibiting hemodynamic instability or cardiogenic shock, recurrent or refractory angina despite medical therapy, life-threatening ventricular arrhythmias (sustained VT or VF), mechanical complications of MI, or acute decompensated heart failure with dynamic ST-T wave changes.

Early Invasive Strategy ( < 24 hours < 24\text{ hours} < 24 hours ) : Indicated for patients with established NSTEMI (elevated cardiac biomarkers), dynamic ischemic ECG changes, or a Global Registry of Acute Coronary Events (GRACE) risk score > 140 > 140 > 140 .

Selective Invasive (Conservative) Strategy : Reserved for low-risk patients (GRACE score < 109 < 109 < 109 ) without recurrent symptoms or objective ischemic signs, managed with non-invasive functional testing prior to discharge.

Anticoagulation and Dual Antiplatelet Therapy (DAPT)

Optimal pharmacological therapy balances ischemic prevention against life-threatening hemorrhage:

Aspirin : An initial loading dose of 162 – 325 mg 162\text{--}325\text{ mg} 162 – 325 mg (non-enteric coated, chewed for rapid buccal absorption) administered immediately, followed by daily maintenance therapy of 81 mg 81\text{ mg} 81 mg indefinitely.

Oral P2Y 12 \text{P2Y}_{12} P2Y 12 ​ Inhibitors :

Ticagrelor : Reversible, non-thienopyridine P2Y 12 \text{P2Y}_{12} P2Y 12 ​ inhibitor ( 180 mg 180\text{ mg} 180 mg loading dose, followed by 90 mg 90\text{ mg} 90 mg BID). Demonstrates faster, more potent, and more consistent platelet inhibition than clopidogrel (PLATO trial).

Prasugrel : Irreversible thienopyridine prodrug ( 60 mg 60\text{ mg} 60 mg loading dose, followed by 10 mg 10\text{ mg} 10 mg daily). Proven superior to clopidogrel in reducing ischemic events and stent thrombosis (TRITON-TIMI 38 trial). Strict Contraindications : Prior history of transient ischemic attack (TIA) or stroke. Generally not recommended in patients aged ≥ 75 years \ge 75\text{ years} ≥ 75 years or body weight < 60 kg < 60\text{ kg} < 60 kg due to heightened intracranial and fatal bleeding risks.

Clopidogrel : Thienopyridine ( 600 mg 600\text{ mg} 600 mg loading dose, followed by 75 mg 75\text{ mg} 75 mg daily). Recommended when ticagrelor or prasugrel are contraindicated, in patients requiring concurrent oral anticoagulation ("triple/double therapy"), or when fibrinolysis is administered.

Intravenous Cangrelor : An ultra-short-acting, reversible intravenous P2Y 12 \text{P2Y}_{12} P2Y 12 ​ platelet inhibitor with an instantaneous onset of action and an elimination half-life of 3 – 6 minutes 3\text{--}6\text{ minutes} 3 – 6 minutes (plateau recovery within 1 – 2 hours 1\text{--}2\text{ hours} 1 – 2 hours ). Indicated in critically ill patients undergoing PCI who cannot absorb oral agents due to endotracheal intubation, cardiogenic shock with splanchnic hypoperfusion, therapeutic hypothermia, or when immediate surgical revascularization may be required.

Parenteral Anticoagulation :

Unfractionated Heparin (UFH) : Standard weight-based bolus ( 60 units/kg 60\text{ units/kg} 60 units/kg , max 4000 units 4000\text{ units} 4000 units ) and continuous infusion ( 12 units/kg/hr 12\text{ units/kg/hr} 12 units/kg/hr , max 1000 units/hr 1000\text{ units/hr} 1000 units/hr ) titrated to maintain an activated partial thromboplastin time (aPTT) between 50 – 70 seconds 50\text{--}70\text{ seconds} 50 – 70 seconds (or activated clotting time [ACT] 200 – 250 seconds 200\text{--}250\text{ seconds} 200 – 250 seconds during PCI with GP IIb/IIIa inhibitors; 250 – 300 seconds 250\text{--}300\text{ seconds} 250 – 300 seconds without). UFH is favored in patients with severe renal failure (creatinine clearance < 30 mL/min < 30\text{ mL/min} < 30 mL/min ) or impending cardiothoracic surgery.

Bivalirudin : Direct thrombin inhibitor; serves as an alternative to heparin plus glycoprotein IIb/IIIa inhibitors in patients with acute heparin-induced thrombocytopenia (HIT) or high bleeding risk.

Enoxaparin : Low-molecular-weight heparin ( 1 mg/kg 1\text{ mg/kg} 1 mg/kg subcutaneous every 12 hours); requires dose reduction in renal impairment.

Fondaparinux : Factor Xa inhibitor; associated with lower bleeding in NSTEMI, but strictly contraindicated as the sole anticoagulant during PCI due to catheter-related thrombosis; must be co-administered with UFH if PCI is performed.

Type 1 vs. Type 2 Myocardial Infarction

The Fourth Universal Definition of Myocardial Infarction delineates distinct pathophysiological mechanisms that fundamentally alter ICU management:

Type 1 Myocardial Infarction : Myocardial necrosis caused by spontaneous atherothrombotic coronary artery disease. A vulnerable fibroatheroma undergoes plaque rupture, ulceration, fissuring, or erosion, precipitating intraluminal thrombus formation in one or more coronary arteries with reduction of distal myocardial blood flow.

Type 2 Myocardial Infarction : Myocardial injury with necrosis arising from a critical imbalance between myocardial oxygen supply and demand in the absence of acute atherothrombosis. In critically ill patients, common triggers include:

Supply Reduction : Severe hypoxemia (respiratory failure, severe ARDS), severe acute blood loss anemia, profound hypotension / shock (septic, hemorrhagic, distributive), vasospasm, coronary dissection, or microvascular dysfunction.

Demand Elevation : Severe sustained tachyarrhythmias (atrial fibrillation with RVR, sustained SVT/VT), hypertensive emergency, severe aortic valve stenosis, and intense endogenous or exogenous catecholamine surges.

Clinical Distinction and Critical Care Pitfalls

In the ICU, distinguishing Type 1 from Type 2 MI is vital:

Biomarkers : Both entities present with elevated cardiac troponin with a characteristic rise and/or fall pattern above the 99th percentile upper reference limit. However, troponin elevation in septic shock is ubiquitous ( > 50 % > 50\% > 50% of patients) and reflects supply-demand mismatch, microcirculatory thrombosis, or direct cytokine-mediated cardiomyocyte injury.

Electrocardiography & Imaging : Type 1 MI classically exhibits focal regional ST elevations, ST depressions, T-wave inversions, and corresponding regional wall motion abnormalities (RWMAs) matching a single coronary anatomical distribution on echocardiography. Type 2 MI frequently displays non-focal subendocardial ischemia (diffuse ST depressions) or global ventricular hypokinesis without discrete territorial wall motion defects.

Therapeutic Strategy : Patients with Type 1 MI require immediate revascularization (PCI or CABG), aggressive DAPT, and anticoagulation. In contrast, patients with Type 2 MI do not benefit from emergent coronary angiography or empiric DAPT; exposure to potent antithrombotics drastically increases bleeding morbidity without addressing the underlying pathology. Management of Type 2 MI requires identifying and correcting the underlying physiological trigger: restoring arterial oxygenation, transfusing red blood cells for severe anemia (targeting hemoglobin ≥ 7 – 8 g/dL \ge 7\text{--}8\text{ g/dL} ≥ 7 – 8 g/dL ), titrating vasopressors to reverse shock, and achieving rate control for tachyarrhythmias.

Note

Cardiac troponin elevation alone in a critically ill patient with septic shock or respiratory failure does not equate to acute atherothrombotic plaque rupture. Never reflexively initiate dual antiplatelet therapy or therapeutic anticoagulation for a secondary Type 2 MI; doing so markedly increases gastrointestinal and procedural bleeding risks while failing to treat the underlying driver of myocardial oxygen deficit.

Mechanical Complications of Acute Myocardial Infarction

Mechanical complications of AMI are catastrophic, life-threatening events that classically peak 3 to 7 days 3\text{ to }7\text{ days} 3 to 7 days post-infarction , corresponding to the period of maximal coagulative necrosis, neutrophilic infiltration, macrophage-mediated lysis, and collagen degradation prior to mature fibrotic scar organization. Although modern primary PCI has reduced their incidence to < 1 % < 1\% < 1% , they carry an in-hospital mortality exceeding 50 % to 90 % 50\%\text{ to }90\% 50% to 90% if not rapidly diagnosed and surgically managed. MECHANICAL COMPLICATIONS OF AMI (DAYS 3-7)

  • │
  • ┌──────────────────────────┼──────────────────────────┐
  • ▼ ▼ ▼
  • VENTRICULAR SEPTAL PAPILLARY MUSCLE LEFT VENTRICULAR
  • RUPTURE (VSR) RUPTURE (PMR) FREE WALL RUPTURE
  • Anterior/Inferior MI • Inferior/Posterior MI • Anterior/Lateral MI
  • Harsh holosystolic • Posteromedial muscle • Blowout: Tamponade, PEA

murmur + thrill (solitary PDA blood) • Pseudoaneurysm:

  • O2 step-up >= 7% • Acute flash pulmonary narrow neck, high
  • RA to RV/PA edema, soft murmur rupture risk
  • IABP / Impella bridge • Giant v-waves on PCWP • Emergency pericardiocentesis
  • Urgent surgical repair • Emergent valve surgery + open thoracotomy
  • 1. Ventricular Septal Rupture (VSR)

Ventricular septal rupture results from transmural infarction involving either the anterior wall (occlusion of the left anterior descending [LAD] artery, causing apical septal defects) or the inferior/posterior wall (occlusion of the right coronary artery [RCA] or posterior descending artery [PDA], producing complex basal septal defects).

Clinical Presentation : Sudden hemodynamic deterioration, rapidly progressive cardiogenic shock, and biventricular failure. Physical examination reveals a loud, harsh holosystolic murmur heard best along the left lower sternal border, accompanied by a palpable systolic thrill in > 50 % > 50\% > 50% of patients.

Invasive Hemodynamic Confirmation : Pulmonary artery catheterization (PAC) demonstrates an oxygen saturation step-up ≥ 7 % to 10 % \ge 7\%\text{ to }10\% ≥ 7% to 10% between the right atrium (mixed venous blood, typical SvO 2 ≈ 60 % \text{SvO}_2 \approx 60\% SvO 2 ​ ≈ 60% ) and the right ventricle / pulmonary artery (elevated to > 75 % – 80 % > 75\%\text{--}80\% > 75% – 80% ) due to left-to-right shunting of oxygenated left ventricular blood across the defect.

Echocardiography : Transthoracic (TTE) or transesophageal (TEE) echocardiography with color Doppler directly visualizes the septal disruption, delineates defect size and anatomy (simple vs. serpentine/complex), demonstrates high-velocity left-to-right flow, and assesses right ventricular systolic strain.

Critical Care Stabilization : The immediate objective is afterload reduction to decrease left-to-right shunt fraction and augment systemic forward flow. If blood pressure permits, titrate intravenous sodium nitroprusside. Mechanical circulatory support (MCS) is critical:

Intra-Aortic Balloon Pump (IABP) : Provides counterpulsation, decreasing LV afterload during systole and enhancing coronary perfusion during diastole, diminishing left-to-right shunt volume.

Percutaneous Microaxial Flow Pump (Impella) : Directly unloads the left ventricle, reduces LV end-diastolic volume and pressure, and minimizes shunt fraction.

Definitive Management : Urgent surgical repair with a Dacron patch or percutaneous transcatheter closure in selected high-risk surgical candidates. Without intervention, 30-day mortality exceeds 90 % 90\% 90% .

2. Papillary Muscle Rupture (Acute Mitral Regurgitation)

Acute papillary muscle rupture is the most lethal cause of acute mitral regurgitation (MR) post-MI:

Anatomical Vulnerability : The mitral valve apparatus contains two papillary muscles with starkly different arterial supplies:

Posteromedial Papillary Muscle : Receives a solitary blood supply from the posterior descending artery (PDA; branching from the RCA in 85 % 85\% 85% of right-dominant individuals or the LCx in left-dominant systems). This single blood supply renders it exceptionally vulnerable to ischemic necrosis and complete rupture during acute inferior or posterior MI (responsible for > 75 % > 75\% > 75% of rupture cases).

Anterolateral Papillary Muscle : Has a dual, redundant blood supply from both the left anterior descending (LAD) diagonal branches and the left circumflex (LCx) obtuse marginal branches, making rupture exceedingly rare.

Clinical Presentation : Abrupt, catastrophic clinical collapse characterized by acute flash pulmonary edema , extreme dyspnea, pink frothy sputum, tachypnea, and refractory cardiogenic shock.

Physical Examination Trap : Unlike chronic mitral regurgitation, the systolic murmur of acute severe MR is frequently soft, early-systolic, or completely absent (silent MR) . Because the normal-sized, non-compliant left atrium experiences a sudden massive volume overload, left atrial and left ventricular pressures rapidly equilibrate during mid-to-late systole, abolishing the late-systolic pressure gradient required to generate a loud, turbulent holosystolic murmur.

Invasive Hemodynamics : PAC reveals marked elevation of pulmonary capillary wedge pressure (PCWP) with giant, tall v v v -waves (often peaking at 40 – 60 mmHg 40\text{--}60\text{ mmHg} 40 – 60 mmHg ), representing the forceful regurgitant jet ejecting backward into an unprepared, non-distensible left atrium during ventricular systole.

Echocardiography : Bedside TTE or TEE reveals a hyperdynamic left ventricle with an underfilled end-systolic volume, a flail mitral leaflet (typically the P2/P3 scallop of the posterior leaflet), a mobile ruptured muscle head prolapsing into the left atrium during systole, and an eccentric, high-velocity regurgitant jet directed away from the flail leaflet.

Management : Emergent surgical consultation for mitral valve replacement (preferred over repair due to extensive necrotic tissue) is mandatory. Temporizing medical stabilization requires immediate IABP placement (substantially reduces LV afterload, lowering regurgitant fraction and pulmonary venous congestion), cautious afterload reduction with nitroprusside if arterial pressure allows, inotropes (dobutamine), and urgent endotracheal intubation with positive-pressure ventilation.

3. Left Ventricular Free Wall Rupture (LVFWR)

Left ventricular free wall rupture occurs in approximately 1 % to 2 % 1\%\text{ to }2\% 1% to 2% of transmural infarctions, most commonly involving the anterior or lateral walls following occlusion of the LAD or LCx:

Acute Blowout Rupture : A full-thickness tear through the necrotic myocardium into the pericardial space. Characterized by sudden, catastrophic hemopericardium, acute cardiac tamponade, electromechanical dissociation (pulseless electrical activity [PEA] arrest), and rapid death within minutes. Survival is rare and requires instantaneous bedside pericardiocentesis followed by emergency room thoracotomy / sternotomy.

Subacute Rupture / Pseudoaneurysm : A contained rupture where the myocardial defect is sealed by adherent parietal pericardium, epicardial fibrous tissue, and organized mural thrombus, preventing immediate free hemorrhage:

Pseudoaneurysm (False Aneurysm) : The wall of the cavity is composed entirely of pericardium and thrombus, without myocardial elements. It has a narrow neck connecting to the LV cavity (neck-to-cavity diameter ratio < 0.5 < 0.5 < 0.5 ). Because it lacks structural tensile strength, it possesses an exceptionally high risk of secondary catastrophic free rupture and requires urgent surgical resection .

True Left Ventricular Aneurysm : An area of thinned, scarred, dyskinetic or akinetic full-thickness myocardium resulting from late remodeling. It features a wide neck (neck-to-cavity ratio > 0.5 > 0.5 > 0.5 ). True aneurysms rarely rupture; complications include mural thrombus formation, systemic embolization, ventricular tachyarrhythmias, and heart failure.

Clinical Presentation of Contained Rupture : Recurrent or persistent pleuritic chest pain, syncope, unexplained hypotension, elevated jugular venous pressure, pulsus paradoxus ( > 10 mmHg > 10\text{ mmHg} > 10 mmHg inspiratory drop in systolic arterial pressure), muffled heart sounds, and low-voltage QRS with electrical alternans on ECG.

Critical Management : Immediate bedside echocardiography to confirm pericardial fluid with tamponade physiology (right ventricular diastolic collapse, right atrial late-diastolic collapse, exaggerated respiratory variation across the mitral and tricuspid valves). Emergent surgical repair with pericardial patch grafting; therapeutic pericardiocentesis is performed strictly as a life-saving temporizing bridge when cardiac arrest is imminent.

Mechanical Complication Culprit Vessel & Peak Timing Key Physical Exam Findings Hemodynamic / PAC Findings Bedside Echocardiographic Features Immediate Medical & Surgical Management

Ventricular Septal Rupture (VSR) LAD (apical) or RCA (basal); Days 3–7 Harsh, loud holosystolic murmur at LLSB; palpable thrill in > 50 % > 50\% > 50% Oxygen saturation step-up ≥ 7 % – 10 % \ge 7\%\text{--}10\% ≥ 7% – 10% between RA and RV/PA Color Doppler reveals turbulent left-to-right trans-septal jet; RV volume overload Afterload reduction (nitroprusside if MAP allows); IABP or Impella; urgent surgical patch repair

Papillary Muscle Rupture (PMR) RCA / PDA (posteromedial muscle, single supply); Days 3–7 Acute flash pulmonary edema, pink frothy sputum; murmur often soft, early-systolic, or silent Giant, tall v v v -waves ( > 40 mmHg > 40\text{ mmHg} > 40 mmHg ) on PCWP tracing Flail mitral leaflet; ruptured muscle head prolapsing into LA; eccentric severe MR Emergent IABP placement; inotropes; afterload reduction; emergent mitral valve replacement

LV Free Wall Rupture (Blowout) LAD or LCx; Days 3–7 Sudden hemodynamic collapse, muffled heart sounds, elevated JVP Loss of arterial pressure; equalization of diastolic filling pressures Massive pericardial effusion; severe right atrial and RV diastolic collapse (tamponade) Immediate pericardiocentesis temporizing bridge; emergency thoracotomy / open surgical repair

LV Pseudoaneurysm (Contained Rupture) LAD or LCx; Days 5–14 Recurrent chest pain, syncope, friction rub, pulsus paradoxus Elevated JVP; pulsus paradoxus on arterial line tracing Pericardial sack cavity with narrow neck (neck-to-body ratio < 0.5 < 0.5 < 0.5 ); turbulent bidirectional flow Urgent surgical patch resection and repair to prevent catastrophic secondary free rupture

Right Ventricular Infarction Proximal RCA; Acute to Day 3 Hypotension, clear lungs, elevated JVP, Kussmaul sign Elevated RA/CVP ( > 15 mmHg > 15\text{ mmHg} > 15 mmHg ) with normal to low PCWP ( < 12 mmHg < 12\text{ mmHg} < 12 mmHg ) Dilated, hypokinetic RV; flattened interventricular septum; underfilled LV Isotonic crystalloid boluses ( 1 – 2 L 1\text{--}2\text{ L} 1 – 2 L ); dobutamine; avoid nitrates, morphine, and diuretics

Right Ventricular Infarction

Right ventricular myocardial infarction complicates approximately 30 % to 50 % 30\%\text{ to }50\% 30% to 50% of acute inferior STEMIs , resulting from acute atherothrombotic occlusion of the proximal right coronary artery (RCA) upstream of the acute right ventricular marginal branches. In rare cases, it can result from occlusion of a dominant left circumflex artery supplying the inferior RV wall.

Pathophysiology and Ventricular Interdependence

The right ventricle is a thin-walled, compliant chamber designed to operate against low pulmonary vascular resistance (PVR). When extensive RV ischemia occurs, RV free-wall contractility drops precipitously, producing severe RV systolic failure and dilatation:

Preload Impairment of the Left Ventricle : The failing, stunned RV cannot generate sufficient transpulmonary forward flow to fill the left atrium and ventricle. As a result, left ventricular end-diastolic volume (LV preload) drops severely, precipitating an acute fall in stroke volume, low cardiac output, and profound systemic hypotension.

Ventricular Interdependence : Because the heart is constrained within the non-distensible fibrous pericardium, acute RV dilatation increases intrapericardial pressure. This forces the interventricular septum to shift leftward into the left ventricular cavity ("septal flattening" or reverse septal bowing), further impairing LV diastolic filling.

Clinical and Electrocardiographic Diagnosis

The classical clinical presentation features a hallmark physical triad:

Systemic Hypotension : From severely diminished LV preload and forward cardiac output.

Clear Lung Fields on Auscultation : Absence of pulmonary rales because left atrial and pulmonary capillary wedge pressures remain low or normal.

Marked Jugular Venous Distension (JVD) : High right atrial pressures manifesting as jugular distension, frequently with Kussmaul sign (a paradoxical inspiratory elevation or lack of fall in jugular venous pressure due to the inability of the non-compliant, stiff RV to accommodate augmented venous return during inspiration).

On the standard 12-lead ECG, inferior ST-elevation (leads II, III, aVF) is observed, with ST elevation in lead III typically greater than lead II. However, diagnosis requires right-sided precordial leads ( V 3 R – V 6 R V_3R\text{--}V_6R V 3 ​ R – V 6 ​ R ) :

ST elevation ≥ 1.0 mm \ge 1.0\text{ mm} ≥ 1.0 mm in lead V 4 R V_4R V 4 ​ R (5th intercostal space, right midclavicular line) is the most useful single electrocardiographic marker of acute right ventricular infarction (sensitivity and specificity roughly 80 % 80\% 80% to 90 % 90\% 90% when recorded early).

Warning

Lead V 4 R V_4R V 4 ​ R ST-segment elevations are transient and frequently resolve within 10 to 12 hours 10\text{ to }12\text{ hours} 10 to 12 hours of symptom onset. Always obtain immediate right-sided precordial leads in any patient presenting with acute inferior STEMI or unexplained hypotension.

Hemodynamic and Critical Care Management

Management of RV infarction is fundamentally distinct from isolated LV infarction:

Aggressive Preload Optimization : The ischemic RV functions as a passive conduit and requires elevated right-sided filling pressures ( C V P ≈ 15 – 18 mmHg CVP \approx 15\text{--}18\text{ mmHg} C V P ≈ 15 – 18 mmHg ) to generate transpulmonary forward flow. Administer rapid intravenous infusions of isotonic crystalloid ( 500 – 1000 mL 500\text{--}1000\text{ mL} 500 – 1000 mL boluses, up to 2 – 3 L 2\text{--}3\text{ L} 2 – 3 L ) to restore cardiac output and arterial blood pressure.

Strict Avoidance of Preload-Reducing Agents : Nitrates (sublingual or IV nitroglycerin), morphine, diuretics, and ACE inhibitors are strictly contraindicated . Inadvertent administration of venodilators severely diminishes systemic venous return, precipitating immediate, catastrophic hemodynamic collapse.

Inotropic Support : If volume loading raises CVP above 15 – 18 mmHg 15\text{--}18\text{ mmHg} 15 – 18 mmHg without restoring mean arterial pressure (MAP ≥ 65 mmHg \ge 65\text{ mmHg} ≥ 65 mmHg ) or cardiac index, initiate intravenous dobutamine ( 2.5 – 10 μ g/kg/min 2.5\text{--}10\mu\text{g/kg/min} 2.5 – 10 μ g/kg/min ) to enhance RV contractility. If vasodilation worsens hypotension, co-administer norepinephrine to maintain coronary perfusion pressure.

Maintenance of Atrioventricular Synchrony : In the stiff, non-compliant right ventricle, synchronized right atrial contraction ("atrial kick") contributes up to 30 % to 40 % 30\%\text{ to }40\% 30% to 40% of RV filling. Atrioventricular dyssynchrony (e.g., atrial fibrillation or complete heart block) causes severe hemodynamic deterioration. High-grade AV block must be treated promptly with temporary sequential atrioventricular (AV) pacing, and atrial fibrillation requires immediate electrical cardioversion.

Emergent Reperfusion : Immediate primary PCI of the culprit proximal RCA is the definitive therapy, resulting in dramatic and rapid recovery of RV performance.